The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of 16.7% in the first half of the forecast period. In 2016, the anti-fibrotics held the largest market share (52%) followed by the tyrosine kinase inhibitors.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 162-page report you will receive 57 tables and 97 figures– all unavailable elsewhere.
The 162-page report provides clear detailed insight into the global anti-idiopathic pulmonary fibrosis drugs market size. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Anti-Idiopathic Pulmonary Fibrosis Drugs market forecasts to 2027
• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by mechanism of action:
– Antifibrotics
– Tyrosine Kinase Inhibitors
– Anti-inflammatory Drugs
– Immunosuppressants
– Other MoA
• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by Innovator and Off-label drugs:
– Innovator Drugs
– Off-label Drugs
• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– US
– Japan
– EU5: Germany, France, the UK, Italy, Spain
– Rest of Europe
– Rest of World
• This report provides individual revenue forecasts to 2027 for these marketed drugs:
– Esbriet
– Ofev
• Our study gives qualitative analysis of the anti-idiopathic pulmonary fibrosis drugs market. It discusses:
– Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the G7 markets (Historical 2010-2015, 2016 data, Forecast 2017-2027)
– Epidemiology of Idiopathic Pulmonary Fibrosis by disease severity
– Epidemiology of Idiopathic Pulmonary Fibrosis by gender
– Discussion on novel clinical molecules under development for the treatment of Idiopathic Pulmonary Fibrosis
– Pricing and Reimbursement Overview on Ofev and Esbriet (by NICE, SMC, PBAC, CADTH, G-BA, HAS)
– A SWOT Analysis on the anti-idiopathic pulmonary fibrosis drugs market
• Our study discusses the marketed anti-idiopathic pulmonary fibrosis drugs and pipeline anti-idiopathic pulmonary fibrosis drugs from these companies:
– Actelion
– Afferent Pharmaceuticals
– Asahi Kasei Pharma
– Bellerophon Therapeutics
– Biogen
– Boehringer Ingelheim
– FibroGen
– Galapagos
– Galecto Biotech
– Genentech
– Global Blood Therapeutics
– GSK
– Kadmon Pharmaceuticals
– LTT Bio-Pharma
– MediciNova
– Merck
– Moerae
– Pacific Therapeutics
– Promedior
– ProMetic Life Sciences
– Roche
– Sanofi
– Teva
– Zai Lab
Visiongain’s study is intended for anyone requiring commercial analyses for the global Anti-Idiopathic Pulmonary Fibrosis Drugs Market. You find data, trends and predictions.
Buy our report today Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027: Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs, Off-label Drugs.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report Include:
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain
2. Introduction to the Idiopathic Pulmonary Fibrosis (IPF)
2.1 What is IPF?
2.2 Aetiology – Causes and Risk Factors
2.3 Symptoms
2.4 Stages of IPF
2.5 Diagnosis
2.5.1 Diagnostic Tests
2.5.2 Pulmonary Function Testing/Lung Function Testing
2.5.3 Oximetry
2.5.4 Lung Biopsy
2.5.5 Chest X-ray
2.5.6 Computerized Tomography (CT)
2.5.7 Echocardiogram
2.6 Epidemiology
2.6.1 Methodology
2.6.2 Epidemiology by Country
2.6.3 Epidemiology by Disease Severity
2.6.4 Epidemiology by Gender
2.6.5 Historical Prevalence in Major Markets
2.6.6 Forecast of IPF in Major Markets: 2016-2027
2.6.6.1 The US
2.6.6.2 France
2.6.6.3 Germany
2.6.6.4 The United Kingdom
2.6.6.5 Italy
2.6.6.6 Spain
2.6.6.7 Japan
2.7 Humanistic and Economic Burden
2.7.1 Co-morbidities
2.7.2 Mortality
2.7.3 Healthcare Utilization & Economic Burden
2.8 Prevention and Treatment
2.8.1 Guidelines
2.8.2 Non-pharmacologic Management
2.8.2.1 Quit Smoking
2.8.2.2 Oxygen therapy
2.8.2.3 Pulmonary Rehabilitation
2.8.2.4 Vaccination
2.8.2.5 Maintain Healthy Weight
2.8.2.6 Lung Transplantation
2.8.3 Pharmacologic Treatments
3. Introduction to the Global Anti- Anti-Idiopathic Pulmonary Fibrosis Drugs Market
3.1 Market Structure
3.2 Market Definition and Scope
3.3 Classification by Mechanism of Action
3.3.1 Anti-fibrotics
3.3.2 Tyrosine Kinase Inhibitors
3.3.3 Anti-inflammatory Drugs
3.3.4 Immunosuppressants
3.3.5 Other Mechanisms
3.4 Classification by Innovator or Off-label Drugs
3.4.1 Innovator Drugs
3.4.2 Off-label Drugs
4. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2017-2027
4.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2016
4.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2017-2027
4.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action
4.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Mechanism of Action: Forecast 2017-2027
4.4.1 Global Anti-fibrotics Drugs Market Forecast, 2016-2027
4.4.2Global Tyrosine Kinase Inhibitors Drugs Market Forecast, 2016-2027
4.4.3 Global Anti-inflammatory Drugs Market Forecast, 2016-2027
4.4.4 Global Immunosuppressants Drugs Market Forecast, 2016-2027
4.4.5 Other MoA Drugs Market Forecast, 2016-2027
4.4.6 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Mechanism of Action: Share Forecast 2017-2027
4.5 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label Drugs, 2016
4.5.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label drugs: Forecast 2017-2027
4.5.1.1 Global Innovator Drugs Market Forecast, 2016-2027
4.5.1.2 Global Off-label Drugs Market Forecast, 2016-2027
4.5.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Off-label Drugs: Share Forecast 2016-2027
4.6 Overall Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Drivers, Restraints and Trends
5. Leading Anti-Idiopathic Pulmonary Fibrosis Drugs
5.1 Snapshot of Anti-Idiopathic Pulmonary Fibrosis Drugs’ 2016 Sales, Historical Sales, & Forecast 2017-2027
5.1.1 Esbriet
5.1.1.1 Esbriet: Drug Profile
5.1.1.2 Esbriet: Historical Sales
5.1.1.3 Esbriet Sales Forecast 2017-2027
5.1.1.4 Esbriet Sales by Geography, 2016
5.1.2 Ofev
5.1.2.1 Ofev: Drug Profile
5.1.2.2 Ofev: Historical Sales
5.1.2.3 Ofev: Forecast 2017-2027
5.1.2.4 Ofev: Sales by Geography, 2016
5.2 Off-label Drugs
6. Leading National Markets Forecast 2017-2027
6.1 Geographical Breakdown of Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
6.2 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region, 2017-2027
6.3 US Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
6.3.1 US Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2017-2027
6.4 EU5 Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
6.4.1 EU5 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2017-2027
6.4.1.1 Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027
6.4.1.2 The UK Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027
6.4.1.3 France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027
6.4.1.4 Spain Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027
6.4.1.5 Italy Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2017-2027
6.5 Japan Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027
6.6 RoW Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2016-2027
7. Research and Development for Treating IPF
7.1 Novel Mechanism of Action of Pipeline Drugs
7.2 Active Pipeline Molecules
7.3 Promising Potential Pipeline Molecules
7.3.1 Phase III Molecules
7.3.1.1 Recomodulin (ART-123)
7.3.2 Phase II Molecule
7.3.2.1 Pamrevlumab (FG-3019)
7.3.2.2 PRM-151
7.3.2.3 Erivedge (Vismodegib)
7.3.2.4 Opsumit (Macitentan)
7.3.2.5 INOpulse
7.3.2.6 GBT-440
7.3.2.7 Tipelukast (MN-001)
7.3.2.8 TD-139
7.3.2.9 BG00011 (STX-100)
7.3.2.10 LT-1001 & LT-1002
7.3.2.11 KD-025 (SLx-2119)
7.3.2.12 SAR 156597
7.3.2.13 PBI4050
7.3.2.14 MK-7264(AF 219)
7.3.2.15 Lebrikizumab
7.3.2.16 GLPG-1690
7.3.3 Phase I trial
7.3.3.1 PXS 4728A
7.3.3.2 PTL 202
7.3.3.3 GSK3008348
7.3.3.4 Omipalisib (GSK-2126458)
7.3.3.5 MMI-0100
7.3.3.6 Deupirfenidone(SD 560)
7.3.3.7 ZL 2012
8. Pricing and Reimbursement Overview
8.1 Ofev
8.1.1 NICE (UK)
8.1.2 SMC (Scotland)
8.1.3 PBAC (Australia)
8.1.4 CADTH (Canada)
8.1.5 G-BA (Germany)
8.1.6 HAS (France)
8.1.7 Overall HTA Challenges
8.2 Esbriet
8.2.1 NICE (UK)
8.2.2 SMC (Scotland)
8.2.3 G-BA (Germany)
8.2.4 HAS (France)
8.2.5 CADTH (Canada)
9. Qualitative Analysis of the Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market
9.1 SWOT Analysis, 2016
10. Leading Companies in the Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
10.1 Roche
10.2 Boehringer Ingelheim
11. Conclusions
Appendices
Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Figures
Figure 1.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation Overview
Figure 2.1: Types of Idiopathic Interstitial Pneumonias
Figure 2.2: Pathogenesis of Idiopathic Pulmonary Fibrosis
Figure 2.3 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (absolute cases)
Figure 2.4 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (%)
Figure 2.5 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Severity, ages 40+, 2016 (%)
Figure 2.6 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Gender in G7 Markets, ages 40+, 2016 (%)
Figure 2.7 Historical Prevalence of IPF in G7 Markets, absolute cases; 2010-2015
Figure 2.8 Historical Prevalence of IPF in G7 Markets, CAGR, 2010-2015
Figure 2.9 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the US, ages 40+: absolute cases, AGR (%), 2016-2027
Figure 2.10 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in France, ages 40+: absolute cases, AGR (%), 2016-2027
Figure 2.11 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Germany, ages 40+: absolute cases, AGR (%), 2016-2027
Figure 2.12 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the UK, ages 40+: absolute cases, AGR (%), 2016-2027
Figure 2.13 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Italy, ages 40+: absolute cases, AGR (%), 2016-2027
Figure 2.14 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Spain, ages 40+: absolute cases, AGR (%), 2016-2027
Figure 2.15 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Japan, ages 40+: absolute cases, AGR (%), 2016-2027
Figure 2.16: Comparison of Recommendations in the 2015 and 2011 Idiopathic Pulmonary Fibrosis Guidelines
Figure 3.1 Anti-Idiopathic Pulmonary Fibrosis Drugs Classification by Mechanism of Action, 2017
Figure 3.2: Inflammatory Pathway in IPF
Figure 4.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 4.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action 2016, Revenue ($m)
Figure 4.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share (%), 2016
Figure 4.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2016-2027: Revenue ($m), AGR (%)
Figure 4.5 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2016 and 2027: Revenue ($m), CAGR (%), 2016 and 2027
Figure 4.6 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: AGR (%), 2016-2027
Figure 4.7 Global Antifibrotic Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 4.8 Global Tyrosine Kinase Inhibitor Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 4.9 Global Anti-inflammatory Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 4.10 Global Immunosuppressants Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 4.11 Global Other MoA Drugs Market: Revenue ($m), AGR (%), 2016-2027 Forecast by Mechanism of Action: Market Share (%), 2016-2027
Figure 4.12 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: Market Share (%), 2016-2027
Figure 4.13 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share Forecast (%), 2017
Figure 4.14 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share (%), 2027
Figure 4.15 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Innovator and Off-label Drugs: Revenue ($m), 2016
Figure 4.16 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Innovator and Off-label Drugs: Market Share (%), 2016
Figure 4.17 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Off-label drugs: Revenue ($m), Global AGR (%), 2016-2027
Figure 4.18 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: Revenue 2016 and 2027 ($m), CAGR 2016-2027 (%)
Figure 4.19 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Inngs Market in the EU5 Countries: Market Share (%), 2016
Figure 6.15 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the EU5 Countries: Revenue ($m), EU5 AGR (%), 2016-2027
Figure 6.16 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the EU5 Countries 2016 and 2027: Revenue ($m), CAGR 2016-2027 (%)
Figure 6.17 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Market Share (%), 2016-2027
Figure 6.18 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Global Market Share (%), 2027
Figure 6.19 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Market Share (%), 2017
Figure 6.20 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Market Share (%), 2027
Figure 6.21 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: AGR (%), 2016-2027
Figure 6.22 Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 6.23 The UK Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 6.24 France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 6.25 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Spain: Revenue ($m), AGR (%), 2016-2027
Figure 6.26 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Italy: Revenue ($m), AGR (%), 2016-2027
Figure 6.27 Japan Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 6.28 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in RoW: Revenue ($m), AGR (%),2016-2027
Figure 7.1 Anti-Idiopathic Pulmonary Fibrosis Clinical Pipeline Segmentation by Phase, 2016
Figure 7.2 Key Molecular Targets of Idiopathic Pulmonary Fibrosis
Figure 7.3 Recomodulin – Mechanism of Action
Figure 9.1 SWOT Analysis of the Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
Figure 10.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Revenue ($m), 2016
Figure 10.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Market Share (%), 2016
Figure 10.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Revenue ($m) 2016
Figure 11.1 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (%)
Figure 11.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
List of Tables
Table 2.1: GAP Index for IPF
Table 2.2: GAP Staging for IPF
Table 2.3: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (absolute cases)
Table 2.4: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Severity, ages 40+, 2016 (absolute cases)
Table 2.5 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016-2027(absolute cases): AGR (%), CAGR (%)
Table 2.6 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the US, ages 40+: absolute cases, AGR (%), CAGR (%), 2016-2027
Table 2.7 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in France, ages 40: absolute cases, AGR (%), CAGR (%), 2016-2027
Table 2.8 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Germany, ages 40+: absolute cases, AGR (%), CAGR (%), 2016-2027
Table 2.9 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the UK, ages 40+: absolute cases, AGR (%), CAGR (%), 2016-2027
Table 2.10 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Italy, ages 40+: absolute cases, AGR (%), CAGR (%), 2016-2027
Table 2.11 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Spain, ages 40+: absolute cases, AGR (%), CAGR (%), 2016-2027
Table 2.12 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Japan, ages 40+: absolute cases, AGR (%), CAGR (%), 2016-2027
Table 3.1: Anti-fibrotic molecular targets and pharmacologic agents
Table 3.2 Mechanism of Action of Innovator Drugs for the treatment of IPF
Table 4.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Markets by Segmentation: Revenue ($m), and Market Share (%), 2016
Table 4.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: AGR (%), 2016-2027
Table 4.5 Global Antifibrotic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.6 Global Tyrosine Kinase Inhibitor Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.7 Global Anti-inflammatory Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.8 Global Immunosuppressants Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.9 Global Other MoA Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.10 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market
Forecast by Mechanism of Action: Market Share (%), 2016-2027
Table 4.11 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.12 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: AGR (%), 2016-2027
Table 4.13 Global Anti-Idiopathic Pulmonary Fibrosis Innovator Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.14 Global Anti-Idiopathic Pulmonary Fibrosis Off-label Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.15 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Off-label Drugs: Market Share (%), 2016-2027
Table 5.1 Branded Anti-Idiopathic Pulmonary Fibrosis Drugs
Table 5.2 Leading Anti-Idiopathic Pulmonary Fibrosis Drug Sales, Revenue ($m), Market Share (%), 2016
Table 5.3 Esbriet: Drug Profile
Table 5.4 Esbriet Sales Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.5 Ofev: Drug Profile
Table 5.6 Ofev Sales Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
Table 6.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: AGR (%), 2016-2027
Table 6.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Market Share (%), 2016-2027
Table 6.5 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.6 Anti-Idiopathic Pulmonary Fibrosis Drugs in the EU5 region: Revenue ($m), Global Market Share (%), EU5 Market Share (%), 2016
Table 6.7 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in EU5 Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.8 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU Region: Market Share (%), 2016-2027
Table 6.9 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: AGR (%), 2016-2027
Table 6.10 Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.11 The UK Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.12 France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.13 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.14 Italy Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.15 Japan nti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.16 RoW Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 7.1: Active Pipeline Molecules under Development for Treating IPF
Table 7.2: Pamrevlumab - Completed and Ongoing Clinical Trials
Table 8.1 Ofev: HTA Agencies’ Decision Outcomes
Table 8.2 Esbriet: HTA Agencies’ Decision Outcomes
Table 10.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Market Share (%), 2016
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
